# Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations

> **NCT07338942** · NA · NOT_YET_RECRUITING · sponsor: **AstraZeneca** · enrollment: 4000 (estimated)

## Conditions studied

- ATTR-CM

## Interventions

- **BEHAVIORAL:** implementation of standard early identification and diagnosis of ATTR

## Key facts

- **NCT ID:** NCT07338942
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2027-11-20
- **Final completion:** 2027-11-20
- **Target enrollment:** 4000 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07338942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07338942, "Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07338942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*